193 related articles for article (PubMed ID: 29596681)
1. Glycoengineering design options for IgG1 in CHO cells using precise gene editing.
Schulz MA; Tian W; Mao Y; Van Coillie J; Sun L; Larsen JS; Chen YH; Kristensen C; Vakhrushev SY; Clausen H; Yang Z
Glycobiology; 2018 Jul; 28(7):542-549. PubMed ID: 29596681
[TBL] [Abstract][Full Text] [Related]
2. Engineering nucleotide sugar synthesis pathways for independent and simultaneous modulation of N-glycan galactosylation and fucosylation in CHO cells.
Prabhu A; Shanmugam D; Gadgil M
Metab Eng; 2022 Nov; 74():61-71. PubMed ID: 36152932
[TBL] [Abstract][Full Text] [Related]
3. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial genome and protein engineering yields monoclonal antibodies with hypergalactosylation from CHO cells.
Chung CY; Wang Q; Yang S; Ponce SA; Kirsch BJ; Zhang H; Betenbaugh MJ
Biotechnol Bioeng; 2017 Dec; 114(12):2848-2856. PubMed ID: 28926673
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms.
Cambay F; Forest-Nault C; Dumoulin L; Seguin A; Henry O; Durocher Y; De Crescenzo G
Mol Immunol; 2020 May; 121():144-158. PubMed ID: 32222585
[TBL] [Abstract][Full Text] [Related]
6. Engineering mammalian cells to produce plant-specific N-glycosylation on proteins.
Larsen JS; Karlsson RTG; Tian W; Schulz MA; Matthes A; Clausen H; Petersen BL; Yang Z
Glycobiology; 2020 Jul; 30(8):528-538. PubMed ID: 32039452
[TBL] [Abstract][Full Text] [Related]
7. Model-Driven Engineering of N-Linked Glycosylation in Chinese Hamster Ovary Cells.
Stach CS; McCann MG; O'Brien CM; Le TS; Somia N; Chen X; Lee K; Fu HY; Daoutidis P; Zhao L; Hu WS; Smanski M
ACS Synth Biol; 2019 Nov; 8(11):2524-2535. PubMed ID: 31596566
[TBL] [Abstract][Full Text] [Related]
8. Chinese hamster ovary (CHO) host cell engineering to increase sialylation of recombinant therapeutic proteins by modulating sialyltransferase expression.
Lin N; Mascarenhas J; Sealover NR; George HJ; Brooks J; Kayser KJ; Gau B; Yasa I; Azadi P; Archer-Hartmann S
Biotechnol Prog; 2015; 31(2):334-46. PubMed ID: 25641927
[TBL] [Abstract][Full Text] [Related]
9. Engineered CHO cells for production of diverse, homogeneous glycoproteins.
Yang Z; Wang S; Halim A; Schulz MA; Frodin M; Rahman SH; Vester-Christensen MB; Behrens C; Kristensen C; Vakhrushev SY; Bennett EP; Wandall HH; Clausen H
Nat Biotechnol; 2015 Aug; 33(8):842-4. PubMed ID: 26192319
[TBL] [Abstract][Full Text] [Related]
10. Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.
Mimura Y; Kelly RM; Unwin L; Albrecht S; Jefferis R; Goodall M; Mizukami Y; Mimura-Kimura Y; Matsumoto T; Ueoka H; Rudd PM
J Immunol Methods; 2016 Jan; 428():30-6. PubMed ID: 26627984
[TBL] [Abstract][Full Text] [Related]
11. Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern.
Schähs M; Strasser R; Stadlmann J; Kunert R; Rademacher T; Steinkellner H
Plant Biotechnol J; 2007 Sep; 5(5):657-63. PubMed ID: 17678502
[TBL] [Abstract][Full Text] [Related]
12. An efficient method to control high mannose and core fucose levels in glycosylated antibody production using deoxymannojirimycin.
Shalel Levanon S; Aharonovitz O; Maor-Shoshani A; Abraham G; Kenett D; Aloni Y
J Biotechnol; 2018 Jun; 276-277():54-62. PubMed ID: 29673624
[TBL] [Abstract][Full Text] [Related]
13. Production of α2,6-sialylated IgG1 in CHO cells.
Raymond C; Robotham A; Spearman M; Butler M; Kelly J; Durocher Y
MAbs; 2015; 7(3):571-83. PubMed ID: 25875452
[TBL] [Abstract][Full Text] [Related]
14. Glycoengineering of CHO Cells to Improve Product Quality.
Wang Q; Yin B; Chung CY; Betenbaugh MJ
Methods Mol Biol; 2017; 1603():25-44. PubMed ID: 28493121
[TBL] [Abstract][Full Text] [Related]
15. Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody.
Falck D; Thomann M; Lechmann M; Koeleman CAM; Malik S; Jany C; Wuhrer M; Reusch D
MAbs; 2021; 13(1):1865596. PubMed ID: 33382957
[TBL] [Abstract][Full Text] [Related]
16. Identification of manipulated variables for a glycosylation control strategy.
St Amand MM; Radhakrishnan D; Robinson AS; Ogunnaike BA
Biotechnol Bioeng; 2014 Oct; 111(10):1957-70. PubMed ID: 24728980
[TBL] [Abstract][Full Text] [Related]
17. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure.
Strasser R; Stadlmann J; Schähs M; Stiegler G; Quendler H; Mach L; Glössl J; Weterings K; Pabst M; Steinkellner H
Plant Biotechnol J; 2008 May; 6(4):392-402. PubMed ID: 18346095
[TBL] [Abstract][Full Text] [Related]
18. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG.
van Berkel PH; Gerritsen J; Perdok G; Valbjørn J; Vink T; van de Winkel JG; Parren PW
Biotechnol Prog; 2009; 25(1):244-51. PubMed ID: 19224598
[TBL] [Abstract][Full Text] [Related]
19. Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N-glycan branching and sialylation.
Yin B; Gao Y; Chung CY; Yang S; Blake E; Stuczynski MC; Tang J; Kildegaard HF; Andersen MR; Zhang H; Betenbaugh MJ
Biotechnol Bioeng; 2015 Nov; 112(11):2343-51. PubMed ID: 26154505
[TBL] [Abstract][Full Text] [Related]
20. Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate.
Shen Z; Wang Y; Xu H; Zhang Q; Sha C; Sun B; Li Q
Int J Biol Macromol; 2021 Jun; 180():494-509. PubMed ID: 33684428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
